TRIM24 Knockout A549 Cell Line

The TRIM24 Knockout A549 Cell Line is a CRISPR/Cas9-edited human cell line designed to ablate TRIM24 gene expression, providing a stable loss-of-function model for lung adenocarcinoma research. This cell line is derived from the A549 parental line and is supplied as an adherent culture, ensuring a consistent genetic background for reproducible experiments. The knockout model allows for definitive functional studies of TRIM24 without the limitations of transient silencing approaches.

The host A549 cell line originates from human lung adenocarcinoma epithelial cells of a 58-year-old male. These cells exhibit characteristics of alveolar type II pneumocytes and adhere in monolayer culture, making them a standard model for respiratory disease, drug metabolism, and toxicity investigations. Their lung adenocarcinoma origin provides a pathologically relevant system for probing oncogenic mechanisms.

TRIM24 functions as an E3 ubiquitin ligase that targets TP53 for ubiquitin-mediated degradation, repressing p53-dependent apoptosis and cell cycle arrest. It also serves as a transcriptional coactivator for nuclear receptors including estrogen receptor alpha (ESR1) and thyroid hormone receptor alpha (THRA), upregulating genes such as MYC and CCND1. TRIM24 is phosphorylated by AKT1 and forms complexes with MDM2 and histone deacetylases, linking growth factor signaling to chromatin remodeling and oncogenic transcription. Upstream transcription factor SP1 further modulates TRIM24 expression.

In A549 cells, TRIM24 overexpression enhances proliferation by suppressing p53 and activating AKT-driven pathways. CRISPR/Cas9-mediated disruption of TRIM24 restores p53 activity and attenuates AKT signaling, thereby reducing cell growth and promoting apoptosis. This knockout cell line is therefore a critical tool for elucidating the interplay between p53 tumor suppression and PI3K/AKT oncogenic signaling in lung adenocarcinoma, as well as for assessing TRIM24??s role in nuclear receptor-coactivated transcription.

The TRIM24 Knockout A549 Cell Line supports a wide array of assays, including Western blotting and RT-qPCR for knockout validation and target gene analysis, RNA-seq for transcriptome profiling, and ChIP-qPCR for chromatin association studies. Functional experiments such as MTS/MTT proliferation, colony formation, and migration assays can evaluate growth and metastatic potential, while flow cytometry enables apoptosis and cell cycle assessment. Co-immunoprecipitation experiments probe interactions with ESR1 or MDM2, and luciferase reporter assays measure transcriptional responses. Additionally, this model is suitable for drug screening to identify compounds with TRIM24-specific effects. For technical assistance, please contact Ascent Research.